About Access Bio
Access Bio is a company based in Somerset (United States) founded in 2001.. Access Bio has raised $22 million across 3 funding rounds from investors including Global Health Investment Corporation. The company has 52 employees as of December 31, 2022. Access Bio offers products and services including CareStart COVID-19 Antigen Home Test, CareStart COVID-19 MDx RT-PCR, CareStart Malaria RDT, CareStart Dengue RDT, and CareStart Flu A&B Plus+. Access Bio operates in a competitive market with competitors including SD Biosensor, Lumos Diagnostics, Fluxergy, Module Innovations and DxGen, among others.
- Headquarter Somerset, United States
- Employees 52 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
- Legal Name Access Bio, Inc. Shs Korean Deposit Receipt Repr. 1 Shs
-
Annual Revenue
$00as on May 20, 2011
-
Net Profit
-
EBITDA
-
Total Equity Funding
$22 M (USD)
in 3 rounds
-
Latest Funding Round
$10 M (USD), Series A
Nov 20, 2020
- Investors
-
Employee Count
52
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Access Bio
Access Bio is a publicly listed company on the KRX with ticker symbol 950130 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Access Bio
Access Bio offers a comprehensive portfolio of products and services, including CareStart COVID-19 Antigen Home Test, CareStart COVID-19 MDx RT-PCR, CareStart Malaria RDT, CareStart Dengue RDT, and CareStart Flu A&B Plus+. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Rapid antigen test for home-based COVID-19 detection.
RT-PCR kit for accurate COVID-19 virus detection.
Test for quick malaria parasite detection.
Rapid test for dengue virus identification.
Test for influenza A and B virus detection.
Funding Insights of Access Bio
Access Bio has successfully raised a total of $22M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $10 million completed in November 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series A — $10.0M
-
First Round
First Round
(20 May 2011)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2020 | Amount | Series A - Access Bio | Valuation |
investors |
|
| Apr, 2016 | Amount | Post-IPO - Access Bio | Valuation |
investors |
|
| May, 2011 | Amount | Series B - Access Bio | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Access Bio
Access Bio has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Global Health Investment Corporation. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Global health technologies are catalyzed by this nonprofit organization.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Access Bio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Access Bio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Access Bio Comparisons
Competitors of Access Bio
Access Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as SD Biosensor, Lumos Diagnostics, Fluxergy, Module Innovations and DxGen, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Biosensors for point-of-care diagnostics are developed by SD Biosensor.
|
|
| domain | founded_year | HQ Location |
Diversified diagnostic assays and readers are developed for point-of-care use.
|
|
| domain | founded_year | HQ Location |
Provides diagnostic devices and software for clinical and veterinary point-of-care testing.
|
|
| domain | founded_year | HQ Location |
Diagnostics strip for bacterial detection
|
|
| domain | founded_year | HQ Location |
Point-of-care diagnostic products for diabetes and tuberculosis are provided.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Access Bio
Frequently Asked Questions about Access Bio
When was Access Bio founded?
Access Bio was founded in 2001 and raised its 1st funding round 10 years after it was founded.
Where is Access Bio located?
Access Bio is headquartered in Somerset, United States.
Is Access Bio a funded company?
Access Bio is a funded company, having raised a total of $22M across 3 funding rounds to date. The company's 1st funding round was a Series B of $12M, raised on May 20, 2011.
How many employees does Access Bio have?
As of Dec 31, 2022, the latest employee count at Access Bio is 52.
What does Access Bio do?
Access Bio was founded in 2001 and is based in Somerset, United States. Operations focus on the medical diagnostics sector, where in vitro rapid tests, biosensors, and molecular diagnostic products are researched, developed, and manufactured for infectious disease detection. Point-of-care tests for malaria, dengue, G6PD deficiency, and pregnancy are provided, along with molecular diagnostics for Congenital Adrenal Hyperplasia and HPV infections.
Who are the top competitors of Access Bio?
Access Bio's top competitors include SD Biosensor, Lumos Diagnostics and Module Innovations.
What products or services does Access Bio offer?
Access Bio offers CareStart COVID-19 Antigen Home Test, CareStart COVID-19 MDx RT-PCR, CareStart Malaria RDT, CareStart Dengue RDT, and CareStart Flu A&B Plus+.
Is Access Bio publicly traded?
Yes, Access Bio is publicly traded on KRX under the ticker symbol 950130.
Who are Access Bio's investors?
Access Bio has 1 investor. Key investors include Global Health Investment Corporation.
What is Access Bio's ticker symbol?
The ticker symbol of Access Bio is 950130 on KRX.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.